Sontra Medical Appoints Harry G. Mitchell as Chief Financial Officer
September 05 2006 - 2:04PM
PR Newswire (US)
FRANKLIN, Mass., Sept. 5 /PRNewswire-FirstCall/ -- Sontra Medical
Corporation (NASDAQ:SONTD) announced today the appointment of Mr.
Harry G. Mitchell as its Chief Financial Officer, Treasurer and
Vice President of Finance. In this position, Mr. Mitchell will be
responsible for Sontra's accounting and financial operations,
including input to Sontra's business strategic planning. Mr.
Mitchell is a Certified Public Accountant and has been the interim
CFO of Sontra since June 12, 2006. Previously, Mr. Mitchell has
been the Chief Executive Officer and/or Chief Financial Officer for
several medical device and technology companies. Since 2004, Mr.
Mitchell has served as President and Chief Executive Officer of
MedTech Advances, Inc., a privately-held medical device company
focusing in the Diabetes Industry, and has provided financial and
other consulting services to several other corporations. From 1999
to 2004, Mr. Mitchell was Senior Vice President and Chief Financial
Officer of Boston Medical Technologies, Inc., a privately held
medical device and information technology company focusing in the
Diabetes Industry. From 1997 to 1998, Mr. Mitchell was Senior Vice
President, Chief Financial Officer and Treasurer of Focus
Enhancements, Inc., a public company in the video imaging
technology business. Thomas W. Davison, Sontra's Chief Executive
Officer and President stated, "We are pleased to have Harry
Mitchell join us permanently as Chief Financial Officer. Harry has
already had a significant positive impact on our company and has
brought extensive insight into our strategic planning as a result
of his broad experience in finance and the medical device industry.
He is a seasoned executive with mature and emerging public
companies, and I am sure that he will make a substantial
contribution to our corporate goals." About Sontra Medical
Corporation (http://www.sontra.com/) Sontra Medical Corporation is
a technology leader in transdermal science and is developing a
non-invasive, continuous transdermal glucose monitor ("CTGM") for
principal use in the Intensive Care Market. Through its platform
technology, the SonoPrep(R) Permeation System, combined with
technical competencies in transdermal drug formulation, analysis,
delivery systems and biosensors, the Company is creating a new
paradigm in transdermal drug delivery and diagnosis. The CTGM and
other company products are being developed for several billion
dollar market opportunities, all utilizing skin permeation,
chemistry and biosensor technology developed by the Company. In
addition, the Company is developing products for transdermal
delivery of large molecule drugs and vaccines. Any statements
contained in this press release that do not describe historical
facts may constitute forward-looking statements as that term is
defined in the Private Securities Litigation Reform Act of 1995.
Any forward-looking statements contained herein are based on
current expectations, but are subject to a number of risks and
uncertainties. The factors that could cause actual future results
to differ materially from current expectations include, but are not
limited to, risks and uncertainties relating to the Company's
ability to develop, market and sell products based on its
technology, including a continuous transdermal glucose monitor for
the hospital ICU market; the expected size of the market for the
continuous transdermal glucose monitor for the hospital ICU market;
the expected benefits and efficacy of the SonoPrep device in
connection with diagnostics, vaccine delivery, glucose monitoring
and transdermal science; the availability of substantial additional
funding to conduct research and development, clinical studies and
future product commercialization; and, the Company's business,
research, product development, regulatory approval, marketing and
distribution plans and strategies. These and other factors are
identified and described in more detail in our filings with the
SEC, including, without limitation, our respective annual reports
on Form 10-KSB for the year ended December 31, 2005, our most
recent quarterly reports on Form 10-QSB, and our current reports on
Form 8-K. We do not undertake to update these forward-looking
statements made by us. SonoPrep is a registered trademark of Sontra
Medical Corporation. All other company, product or service names
mentioned herein are the trademarks or registered trademarks of
their respective owners. Investor Relations Contact: Harry G.
Mitchell, CFO 508-530-0311 DATASOURCE: Sontra Medical Corporation
CONTACT: Harry G. Mitchell, CFO of Sontra Medical Corporation,
+1-508-530-0311, Web site: http://www.sontra.com/
Copyright
Sontra Medical (MM) (NASDAQ:SONTD)
Historical Stock Chart
From May 2024 to Jun 2024
Sontra Medical (MM) (NASDAQ:SONTD)
Historical Stock Chart
From Jun 2023 to Jun 2024